SCD-HeFTSudden Cardiac Death in Heart Failure Trial
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The first large trial which clearly stated against DFT testing in ICD recipients was SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial): a primary prevention ICD trial that compared single-chamber ICDs with amiodarone or placebo in improving survival in patients with symptomatic heart failure and left ventricular ejection fractions [less than or equal to] 35% [29].
The number of patients that receive an ICD has grown significantly over the last 14 years, particularly after the publication of MADIT-II and SCD-HeFT studies.
Stewart noted, SCD-HeFT showed the benefit is 7-8 lives saved.
The National Institutes of Health-sponsored SCD-HeFT trial showed that preventive implantation of ICDs reduced death by 23 percent in people with heart failure and low ejection fraction, compared to those who did not receive defibrillators.
Gust Bardy, SCD-HeFT study director and president of the Seattle Institute for Cardiac Research in Washington.
Medicare coverage for ICDs in patients who meet SCD-HeFT criteria will mean an extra 500,000 or more ICD implantations per year, placing an anticipated $15 billion annual burden on the economy.
The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) indicates that mortality has decreased to about 7% per year.
In September 2004, it expanded coverage to include patients with nonischemic dilated cardiomyopathy (NIDCM) and removed the QRS interval requirement, in response to a request to reconsider its coverage by the ICD maker Medtronic, on the basis of results of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Implanting ICDs based upon the overly broad criteria established in MADIT-II and SCD-HeFT is a misappropriation of money that could be far better used to enhance the health and longevity of millions of Americans; for example, by helping to provide health insurance coverage for the 45 million Americans who don't have it.
The new secondary analysis of electrophysiologic data from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) shows that QRS duration is not an adequate predictor of mortality risk upon which to base a decision as to who is likely to benefit from implantable cardioverter defibrillator (ICD) therapy, Dr.
An economic analysis of the results of SCD-HeFT showed that placing an implantable cardioverter defibrillator in all patients who met entry criteria would cost about $33,000 for each added life-year, Daniel B.